AbbVie and Anima Biotech Announce Collaboration for the Discovery and Development of mRNA Biology Modulators against Oncology and Immunology Targets

AbbVie (NYSE: ABBV), and Anima Biotech (Anima), today announced a collaboration to discover and develop mRNA biology modulators for three targets across Oncology and Immunology. Anima will use its mRNA Lightning platform to discover novel mRNA biology modulators against the collaboration targets providing AbbVie ...

Related Keywords

, Yochi Slonim , Jonathon Sedgwick , Exchange Commission , Takeda Pharmaceuticals , Linkedin , Twitter , Allergan , Anima Biotech , Allergan Aesthetics , Private Securities Litigation Reform Act , Quarterly Reports ,